ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AXL/FLT3/VEGFR2 Inhibitor KC1036

Its studies are mostly in Esophageal Squamous Cell Carcinoma · Thymus Neoplasms · Sarcoma, Ewing, led by Beijing Konruns Pharmaceutical.

Drug pageAXL/FLT3/VEGFR2 Inhibitor KC1036: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 22, 20237 company-led studies, 6 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Konruns Pharmaceutical76 open or runningphase 3since Dec 22, 2023May 11, 2020Dec 30, 2026phase 3 · NCT06194734

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2020First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04387916 · 207 planned · China
  2. Jan 27, 2022Phase 2 study in Digestive System TumorsNCT05260385 · 133 planned · China
  3. Feb 16, 2022No phase study in Healthy SubjectsNCT05265338 · 12 enrolled · China
  4. Jan 5, 2023Phase 2 study in Thymus NeoplasmsNCT05683886 · 30 planned · China
  5. Dec 22, 2023Phase 3 study in Esophageal Squamous Cell CarcinomaNCT06194734 · 490 planned · China
  6. Aug 19, 2024Phase 2 study in Sarcoma, EwingNCT06564272 · 30 planned · China
  7. Mar 14, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07481058 · 60 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT06194734
  2. Apr 1, 2027Primary completion: phase 2 study in Sarcoma, EwingNCT06564272
  3. Dec 2027Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07481058

TargetBeta

“An orally bioavailable inhibitor of three receptor tyrosine kinases: AXL (UFO), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2), and the vascular endothelial growth factor receptor type 2 (VEGFR2), ”NCIt, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07481058Esophageal Squamous Cell Carcinoma · China2RecruitingDec 202760
NCT06564272Sarcoma, Ewing · China2RecruitingApr 1, 202730
NCT06194734Esophageal Squamous Cell Carcinoma · China3RecruitingDec 30, 2026490
NCT05683886Thymus Neoplasms · China2RecruitingFeb 202530
NCT05265338Healthy Subjects · China–CompletedMar 23, 202212
NCT05260385Digestive System Tumors · China2RecruitingOct 30, 2025133
NCT04387916Advanced Solid Tumors · China1RecruitingOct 31, 2025207

How it is read

Names in the registry

  • “KC1036”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.